WO2008095015A8 - Method of treating recurrent tumors - Google Patents

Method of treating recurrent tumors Download PDF

Info

Publication number
WO2008095015A8
WO2008095015A8 PCT/US2008/052486 US2008052486W WO2008095015A8 WO 2008095015 A8 WO2008095015 A8 WO 2008095015A8 US 2008052486 W US2008052486 W US 2008052486W WO 2008095015 A8 WO2008095015 A8 WO 2008095015A8
Authority
WO
WIPO (PCT)
Prior art keywords
recurrent tumors
treating recurrent
mammal
treating
tumors
Prior art date
Application number
PCT/US2008/052486
Other languages
French (fr)
Other versions
WO2008095015A3 (en
WO2008095015A2 (en
Inventor
Rakesh Jain
Sergey Kozin
Yves Boucher
Original Assignee
Gen Hospital Corp
Rakesh Jain
Sergey Kozin
Yves Boucher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Rakesh Jain, Sergey Kozin, Yves Boucher filed Critical Gen Hospital Corp
Publication of WO2008095015A2 publication Critical patent/WO2008095015A2/en
Publication of WO2008095015A3 publication Critical patent/WO2008095015A3/en
Publication of WO2008095015A8 publication Critical patent/WO2008095015A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity

Abstract

The present invention provides a method of treating a recurring tumor in a mammal in need thereof comprising administering to the mammal a therapeutically effective amount of a vascular endothelial growth factor receptor (VEGFR) antagonist.
PCT/US2008/052486 2007-01-30 2008-01-30 Method of treating recurrent tumors WO2008095015A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89809807P 2007-01-30 2007-01-30
US60/898,098 2007-01-30

Publications (3)

Publication Number Publication Date
WO2008095015A2 WO2008095015A2 (en) 2008-08-07
WO2008095015A3 WO2008095015A3 (en) 2008-11-06
WO2008095015A8 true WO2008095015A8 (en) 2009-08-06

Family

ID=39674772

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/052486 WO2008095015A2 (en) 2007-01-30 2008-01-30 Method of treating recurrent tumors

Country Status (1)

Country Link
WO (1) WO2008095015A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011161217A2 (en) * 2010-06-23 2011-12-29 Palacký University in Olomouc Targeting of vegfr2
CN105213394B (en) * 2014-06-06 2019-04-09 正大天晴药业集团股份有限公司 Quinoline with anti-tumor activity
CN105311029A (en) * 2014-06-06 2016-02-10 正大天晴药业集团股份有限公司 Antineoplastic-activity quinoline derivative

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030108545A1 (en) * 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist

Also Published As

Publication number Publication date
WO2008095015A3 (en) 2008-11-06
WO2008095015A2 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
HK1254663A1 (en) Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
NO2017019I2 (en) Enzalutamide or a pharmaceutically acceptable salt thereof
EA200801521A1 (en) LIGANDS THAT HAVE A SPECIFICITY OF BINDING TO VEGF AND / OR EGFR, AND METHODS OF THEIR USE
AU2006226897B2 (en) Combinations for the treatment of cancer comprising anti-EGFR antibody and VEGFR inhibitors
IL243376A0 (en) Antagonist antibody against epha2 for the treatment of cancer
WO2008130704A3 (en) PDGFRβ-SPECIFIC INHIBITORS
IL193675A0 (en) Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
EP4279140A3 (en) Human antibodies against tissue factor
WO2007127010A3 (en) Diarylthiohydantoin compounds
EP2366716A3 (en) Combinatorial therapy involving alpha5beta1 antagonists
MY151191A (en) Novel antibodies
WO2009142738A3 (en) Compositions and methods for diagnosing and treating cancer
EA200801172A1 (en) LIGANDS HAVING A SPECIFICITY OF BINDING WITH RESPECT TO THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR (EGFR) AND / OR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), AND THEIR APPLICATION
WO2009020933A3 (en) Therapeutic use of anti-tweak receptor antibodies
WO2008091641A3 (en) Compositions and methods for diagnosing and treating cancer
WO2009002808A3 (en) Quinazolinone compounds and methods of use thereof
IL200764A (en) Composition comprising epha3 antibodies for use in the treatment of solid tumors
WO2009132081A3 (en) Monoclonal antibody-based targeting of folate receptors
WO2010099139A3 (en) Combination of an either an anti-igf-ir- antibody or an igf binding protein and a small molecule igf-ir kinease inhibitor
WO2009018226A3 (en) Pharmaceutical combinations comprising a tyrosine kinase inhibitor and an antibody against integrin alpha 1 beta 5 (cd49e)
WO2007033140A3 (en) Prok2 antagonists and methods of use
ZA201000959B (en) The use of extracts or materials extracted from Piper cubeba L. as an effective component in a drug for the treatment of cancer diseases
WO2008095015A3 (en) Method of treating recurrent tumors
GB0610925D0 (en) Use of vascular endothelial growth factor receptor inhibitors for the treatment of cancer
WO2010025135A3 (en) Trimeprazine and ethopropazine derivatives for promoting bone growth

Legal Events

Date Code Title Description
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct app. not ent. europ. phase

Ref document number: 08728575

Country of ref document: EP

Kind code of ref document: A2